Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgène’s armed oncolytic immunotherapies.